1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,400 | 6,600 | 13:05 | |
| 6,350 | 6,650 | 12.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | KEYMED BIO-B Receives USD257 million Upfront Payment from Sale of Ouro Medicines | 1 | AASTOCKS | ||
| 05.06. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 2 | HKEx | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.06. | CMSI: Three Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO , HANSOH PHARMA and KEYMED BIO-B | 8 | AASTOCKS | ||
| 29.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | 1 | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | KEYMED BIO-B (02162): SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | - | HKEx | ||
| 02.04. | A Healthy Return: Drug Spin-off Nets Keymed Up To $320M | 2 | Benzinga.com | ||
| 26.03. | Keymed Biosciences Announces 2025 Annual Results and Business Updates | 343 | PR Newswire | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results.
Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year... ► Artikel lesen | |
| 26.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 23.03. | KEYMED BIO-B (02162): DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 1 | HKEx | ||
| 16.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | - | HKEx | ||
| 10.03. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901) | - | HKEx | ||
| 27.08.25 | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | 350 | PR Newswire | CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,95 | +1,43 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| OCUGEN | 1,050 | 0,00 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 25,150 | +1,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INFLARX | 1,388 | 0,00 % | ANALYSE: InflaRx NV: Könnte die Aktie jetzt komplett einbrechen? - Was Sie über das Wochenende vorbereiten sollten | ||
| EDITAS MEDICINE | 2,180 | +0,93 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,080 | -1,06 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| CARDIOL THERAPEUTICS | 0,907 | +0,44 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 54,10 | -0,18 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 64,04 | -0,59 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 7,960 | -4,07 % | Prediction: I think Telix shares could double in value in 2026. Here's why | ||
| ONCO-INNOVATIONS | 0,471 | -2,89 % | Onco-Innovations meldet Start des Programms zur API-Prozessentwicklung und Zwischenprodukt-Skalierung für seine proprietäre PNKP-Inhibitor-Technologie | Vancouver, Kanada - 9. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, den Beginn der Prozessentwicklung... ► Artikel lesen | |
| TWIST BIOSCIENCE | 65,86 | 0,00 % | Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? | ||
| REPLIGEN | 114,75 | +1,64 % | Repligen Corporation: Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26... ► Artikel lesen | |
| UNIQURE | 24,000 | +0,84 % | uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on... ► Artikel lesen | |
| REVOLUTION MEDICINES | 133,00 | +0,08 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen |
KEYMED BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,350 Euro und damit +6,72 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.